Irmgard Nippert

Prof. Dr. Irmgard Nippert


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2010 in Journal of Community Genetics
Verified
Journal Article
Closed access
PDF file
INIrmgard Nippert
Irmgard Nippert
HHHilary J. Harris
Hilary J. Harris
CJClaire Julian-Reynier
Claire Julian-Reynier
UKUlf Kristoffersson
Ulf Kristoffersson
LKLeo P. Ten Kate
Leo P. Ten Kate
RHRodney Harris
Rodney Harris

3 December 2013 in Journal of Community Genetics
Verified
Journal Article
Closed access
PDF file
INIrmgard Nippert
Irmgard Nippert
CJClaire Julian-Reynier
Claire Julian-Reynier
HHHilary Harris
Hilary Harris
D. Gareth EvansD. Gareth Evans
D. Gareth Evans
CAChristi J. van Asperen
Christi J. van Asperen
JSJörg Schmidtke
Jörg Schmidtke

8 May 2002 in Journal of Biotechnology
Verified
Journal Article
Closed access
INIrmgard Nippert
Irmgard Nippert

3 September 2024 in Genes
Verified
Journal Article
Open access
PDF file
BPBy Ysbrand Poortman
By Ysbrand Poortman
MEMartina Ens-Dokkum
Martina Ens-Dokkum
INIrmgard Nippert
Irmgard Nippert
In 2023, the genetics scientific community celebrated two special anniversaries: the discovery of the double helix structure of DNA was published in 1953 and in 2003 the Human Genome Project was declared completed and made publicly available. To this day, genetics and genomics research is continuing to evolve at high pace and is identifying a steadily increasing number of genes as causal for distinct genetic diseases. The success story of genetics and genomics would not be complete without taking due account of the role of patient advocacy organizations in this process. This paper is based on the personal narrative (oral history) of a father whose daughter was born with a rare genetic disease (RGD) in the 1960s. The first-hand experience of living as a family with an RGD in those days made him a leading pioneer not only in the foundation of patient organizations at national, pan-European, and international levels but also in the development of multi-stakeholder co-operation and networking. Today, patient advocacy organizations play an active role in shaping health and research policies at national, EU, and international levels to ensure that their needs in regard to advancing RGD diagnostics, care, and treatment are addressed.

1 December 2002 in Public Health Genomics
Verified
Journal Article
Closed access
PDF file
INIrmgard Nippert
Irmgard Nippert
BEBirgit Edler
Birgit Edler
CSClaudia Schmidt-Herterich
Claudia Schmidt-Herterich
Objectives: 40 years ago, the sudden increase of births of babies with a range of severe deformities shocked the world. It was caused by the tranquilizer thalidomide. Women who took the drug in the first trimester of pregnancy gave birth to children with a wide but distinctive range of malformations. Thalidomide claimed more than 10,000 victims worldwide. Those who survived are now reaching middle age. Especially women affected by thalidomide may be at special disadvantage because of combined discrimination based on gender and disability. So far, no study has been published that has investigated their quality of life in health and in health care. Methods: A questionnaire using the WHO QOL-BREF instrument for measuring health-related quality of life was distributed among 166 females impaired by thalidomide. A randomized control group matched by age, sex and area of residence filled out a corresponding questionnaire. Results: Women impaired by thalidomide reported significantly lower quality of life in health and health care as compared to their control group. Over a third reported steadily deteriorating conditions, and a statistically significant higher proportion as compared to the controls has already retired from the workforce. They were significantly less frequently married, had fewer children, had less household incomes and were less mobile. However, women impaired by thalidomide are more likely to be satisfied with their safety in daily life, with their physical environment, with their living conditions and with the support they get from their friends. Conclusions: Although there is increasing clinical research on how to use thalidomide as a drug in new therapies, the specific health needs of women impaired by thalidomide are at risk of being neglected.

1 June 2010 in Journal of Community Genetics
Verified
Journal Article
Open access
PDF file
KCKirsty Challen
Kirsty Challen
HHHilary Harris
Hilary Harris
UKUlf Kristoffersson
Ulf Kristoffersson
INIrmgard Nippert
Irmgard Nippert
JSJörg Schmidtke
Jörg Schmidtke
RHRodney Harris
Rodney Harris
It is increasingly recognised that genetics will have to be integrated into all parts of primary health care. Previous research has demonstrated that involvement and confidence in genetics varies amongst primary care providers. We aimed to analyse perceptions of primary care providers regarding responsibility for genetic tasks and factors affecting those perceptions. Postal questionnaire including a hypothetical case management scenario of a cardiac condition with a genetic component was sent to random samples of medically qualified general practitioners in France, Germany, Netherlands, Sweden and UK (n = 1,168). Logistic regression analysis of factors affecting primary care practitioners’ willingness to carry out genetic tasks themselves was conducted; 61% would take a family history themselves but only 38% would explain an inheritance pattern and 16% would order a genetic test. In multivariate analysis, only the country of practice was consistently predictive of willingness to carry out genetic tasks, although male gender predicted willingness to carry out the majority of tasks studied. The stage of career at which education in genetics had been provided was not predictive of willingness to carry out any of the tasks analysed. Country of practice is significantly predictive of attitudes towards genetics in primary care practice and therefore genetic education structure and content in Europe will need to be significantly tailored towards country-specific approaches.